IMMY - Imprimis Pharmaceuticals, Inc.
| Previous Close | 2.22 |
| Open | 2.22 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 2.16 - 2.30 |
| 52 Week Range | 1.35 - 4.49 |
| Volume | 86,230 |
| Avg. Volume | 479,206 |
| Market Cap | 45.868M |
| Beta | 1.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.60 |
| Earnings Date | May 8, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
- Simply Wall St.•5 days ago
Does Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO Salary Compare Well With Others?
Mark Baum took the helm as Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO and grew market cap to US$45.45M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
- PR Newswire•16 days ago
Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt® (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract & Refractive Surgery Medical Meeting
New combination topical drops and other cGMP (current good manufacturing practices) formulations will be showcased SAN DIEGO , April 10, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), ...
- PR Newswire•last month
Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation
SAN DIEGO, March 27, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced it has secured a patent covering the company's innovative MKO (midazolam, ketamine, and ondansetron) Melt® compounded formulation from the US Patent and Trademark office. US Patent 9,918,993 B2 entitled "Pharmaceutical compositions for anesthesiological applications" was issued on March 20, 2018. Imprimis believes that beyond cataract surgery, there are likely more than 100 million annual procedures in the US ranging from dental, obstetric and gynecological, medical imaging procedures (such as MRIs and CAT scans), vasectomies, colonoscopies, dermatological, plastics procedures, orthopedic, otolaryngological, podiatry, emergency room, urology, and psychiatric that may benefit from an IV-free and opioid-free formulation.
- GlobeNewswire•last month
Analysis: Positioning to Benefit within Enbridge Energy Management, Imprimis Pharmaceuticals, Hibbett Sports, Glacier, Regis, and Fox Factory Holding — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, March 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Associated Press•2 months ago
Imprimis reports 4Q loss
The San Diego-based company said it had a loss of 13 cents per share. The pharmaceutical and drug compounding company posted revenue of $7.3 million in the period. For the year, the company reported that ...
- PR Newswire•2 months ago
Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results
SAN DIEGO , March 8, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today reported financial results for the fourth quarter 2017. Notable ...
- ACCESSWIRE•2 months ago
Imprimis Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 8, 2018 / Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018 at 4:30 PM Eastern ...
- ACCESSWIRE•2 months ago
Wired News – Imprimis Pharma Launched New Program for Custom Compounded Ophthalmic Medications
Stock Monitor: Akcea Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 08, 2018 / Active-Investors.com has just released a free research report on Imprimis Pharma, Inc. (NASDAQ: IMMY ...
- PR Newswire•2 months ago
Imprimis Pharmaceuticals to Present at 30th Annual ROTH Conference on March 13, 2018
SAN DIEGO , March 7, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that its Chief Executive Officer, Mark L. Baum ...
- PR Newswire•2 months ago
Imprimis Pharmaceuticals Announces Program for Custom Compounded Ophthalmic Formulations
SAN DIEGO, March 6, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmic-focused pharmaceutical company, today announced that it has launched a new program to provide ophthalmologists and optometrists with custom compounded ophthalmic medications that are increasingly difficult to find and typically needed on an urgent basis. The goal of this program is to provide high-quality compounded medications from an Imprimis FDA-inspected facility and ship it within 24-48 hours. Imprimis intends to make this program available in all 50 US states. "Recent changes in ophthalmic compounding has made it such a challenge to access critical compounded medications, especially for infectious keratitis, where urgent care is essential," stated Marjan Farid, MD, Director of Cornea, Cataract, and Refractive Surgery, Vice-Chair of Ophthalmic Faculty at the Gavin Herbert Eye Institute, University of California Irvine.
- Simply Wall St.•2 months ago
Should You Be Content With Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) Earnings Growth?
Measuring Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) track record of past performance is a valuable exercise for investors. It allows us to understand whether or not the company has met or exceedRead More...
- PR Newswire•2 months ago
Imprimis Pharmaceuticals to Host its Fourth Quarter 2017 Financial Report Conference Call and Webcast on March 8, 2018 at 4:30 p.m. EST
SAN DIEGO, Feb. 15, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced it will release fourth quarter 2017 financial results after the close of trading on Thursday, March 8, 2018. The company will host a conference call at 4:30 p.m. EST/1:30 p.m. PST on the same day to discuss the financial results and recent business developments. To participate in the call, please dial (877) 407-8035 for domestic callers or (201) 689-8035 for international callers. To listen to the webcast, please click here or visit the investor relations section of the Imprimis website at www.ImprimisRx.com. A dial in replay of the call will be available until April 8, 2018. To access the replay, dial (877) 481-4010 domestically or (919) 882-2331 internationally and reference Replay ID: 25720. The webcast replay will be available until June 8, 2018.
- ACCESSWIRE•3 months ago
Today’s Research Reports on Trending Tickers: Corbus Pharmaceuticals and Imprimis Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / January 31, 2018 / U.S. markets fell sharply Tuesday for the second consecutive day. Both the Dow Jones and S&P 500 experienced their largest one day drop of 2018. The Dow Jones ...
- Simply Wall St.•3 months ago
Who Owns Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)?
I am going to take a deep dive into Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure has beenRead More...
- PR Newswire•3 months ago
Imprimis Pharmaceuticals Now Making Available Two Glaucoma Drugs on FDA's Drug Shortage List
SAN DIEGO, Jan. 30, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced that it is now dispensing preservative-free dorzolamide and a preservative-free dorzolamide/timolol formulation after dorzolamide and the commercial products, Cosopt® and Cosopt® PF, were added to the FDA Drug Shortage List.
- ACCESSWIRE•3 months ago
Blog Exposure - Imprimis Pharma Received DEA Manufacturer Certificate for 503B Outsourcing Facility
LONDON, UK / ACCESSWIRE / January 26, 2018 / Active-Investors.com has just released a free research report on Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ). If you want access to this report all you need ...
- PR Newswire•3 months ago
Imprimis Pharmaceuticals is Issued DEA Manufacturer Certificate for its 503B Outsourcing Facility
SAN DIEGO, Jan. 24, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced that following inspection by the US Drug Enforcement Administration, its New Jersey FDA-registered outsourcing facility has been issued a DEA Manufacturer Controlled Substance Registration Certificate. This new registration will further allow Imprimis to leverage its national compounding platform and its relationships with nearly 2,000 ophthalmology and optometric customers, including many of the largest ambulatory surgery centers in the US and numerous hospital systems, in order to provide patients and their healthcare professionals with affordable compounded formulations when they are clinically appropriate. By partnering with physicians to meet their patients' unmet needs, Imprimis continues to make progress in meeting its mission of bringing high quality innovative ophthalmic formulations to physicians and their patients.
- Simply Wall St.•3 months ago
What You Must Know About Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) Financial Strength
Investors are always looking for growth in small-cap stocks like Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), with a market cap of $33.27M. However, an important fact which most ignore is: how financiallyRead More...
- Reuters•3 months ago
Imprimis receives FDA warning over eye medication advertising
The U.S. Food and Drug Administration has issued a warning letter to Imprimis Pharmaceuticals Inc accusing it of making false or misleading claims that its compounded eye medications had the agency's approval. The Dec. 21 letter to San Diego-based Imprimis was posted on the FDA's website on Tuesday. Imprimis is contesting a lawsuit by rival Allergan Plc over allegations it is illegally selling and advertising unapproved drugs.
- Simply Wall St.•3 months ago
NasdaqCM Healthcare Industry: A Deep Dive Into Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)
Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), a USD$37.99M small-cap, operates in the healthcare industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as an aging population,Read More...
- Simply Wall St.•4 months ago
Is Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO Pay Justified?
Mark Baum is the CEO of Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), which has recently grown to a market capitalization of $35.53M. Recognizing whether CEO incentives are aligned with shareholders is aRead More...
- Capital Cube•4 months ago
ETFs with exposure to Imprimis Pharmaceuticals, Inc. : December 26, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Imprimis Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IMMY-US. Comparing the performance and risk of Imprimis Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Simply Wall St.•5 months ago
Imprimis Pharmaceuticals Inc (IMMY): Has Recent Earnings Growth Beaten Long-Term Trend?
For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) track record on a high level, toRead More...
